Abstract 65P
Background
Spleen tyrosine kinase (SYK) is a cytoplasmic nonreceptor tyrosine kinase important for signaling through multiple immunoreceptors across different immune cell types, including B cell receptor (BCR). Inhibition of SYK significantly inhibits the functioning of immunity. The SYK inhibitors entospletinib (IC50 = 7.6 nM) and lanraplenib (IC50 = 120 nM) are highly selective and disrupt kinase activity. Entospletinib (800 mg twice daily) could be beneficial for the treatment of a variety of B cell malignancies, whereas lanraplenib (30 mg once daily) could be used for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Pharmacokinetic data are still limited for entospletinib and lanraplenib. Therefore, we are interested to gain insights into the impact of the efflux transporters P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2) and influx transporters organic anion transporting polypeptides (OATP’s) on the pharmacokinetics of these SYK inhibitors.
Methods
We used wild-type, single and combined Abcb1a/1b and/or Abcg2, and Oatp1a/1b deficient mouse strains. Entospletinib (10 mg/kg) and lanraplenib (10 mg/kg) were administered simultaneously to the mice by oral gavage. At several time points, blood samples were collected via the tail vein and the experiment was terminated using cardiac puncture followed by cervical dislocation.
Results
A slight increase in plasma exposure of entospletinib was observed in Abcb1a/1b;Abcg2-/- compared to wild-type, but not for lanraplenib. Brain exposure of both drugs was clearly restricted by ABC transporters, with a 3.6-fold increase in brain penetration for entospletinib and 12.1-fold for lanraplenib comparing the knockout strain with wild-type. We observed only a slight influence of OATP transporters on the tissue distribution of lanraplenib, but not of entospletinib.
Conclusions
ABC transporters play an important role in the brain disposition of entospletinib and lanraplenib, although they have only a slight impact on the plasma exposure of entospletinib. The role for the OATP uptake transporters seems to be less prominent for both drugs, but they might be involved in the tissue disposition of lanraplenib, but not of entospletinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Schinkel Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
52P - Antitumor efficacy of polypyrrole-polyethyleneimine nanocomplex to target B-cell lymphoma
Presenter: Thi Thuy Nguyen
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
Presenter: Francesco Bertoni
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Inhibition of ATM vs ATR in combination with radiotherapy affects cellular toxicity and expression of immune checkpoint molecules differently in HNSCC
Presenter: Tina Jost
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells
Presenter: Martin Hohenegger
Session: Cocktail & Poster Display session
Resources:
Abstract
56P - Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma
Presenter: Kelsey Gauthier
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Deciphering the role of E2F transcription factor-1 in glutamine metabolism
Presenter: Katharina Huber
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low-expressing breast cancer cells and organoid mode
Presenter: Maryam Arshad
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - The influence of the ABCB1, ABCG2 and OATP1 transporters and the CYP3A enzyme on the bioavailability and tissue distribution of TPX-0131
Presenter: Jamie Rijmers
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - MAPKAP1/SIN1: A promising therapeutic target in resistant BRAF-mutated melanoma
Presenter: Emilien Ezine
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - The cysteine-rich protein 61 (Cyr61) contributes to tumor proliferation and invasion via HGF-mediated NF-kB signaling pathway in human hepatocellular carcinoma
Presenter: Jiyoon Jung
Session: Cocktail & Poster Display session
Resources:
Abstract